| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
18,220 |
16,397 |
$7.74M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
25,901 |
23,800 |
$7.10M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
19,044 |
17,991 |
$4.71M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
5,493 |
5,162 |
$4.01M |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
3,284 |
3,052 |
$1.64M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
5,839 |
5,538 |
$868K |
| 70450 |
Computed tomography, head or brain; without contrast material |
5,468 |
5,086 |
$826K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
1,554 |
1,459 |
$487K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
352 |
322 |
$412K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
1,200 |
1,121 |
$411K |
| G0378 |
Hospital observation service, per hour |
4,296 |
2,195 |
$154K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
5,976 |
5,055 |
$138K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
984 |
855 |
$136K |
| 70496 |
|
168 |
157 |
$113K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,024 |
759 |
$103K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
1,390 |
1,029 |
$78K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
256 |
209 |
$47K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
887 |
860 |
$44K |
| 93971 |
|
793 |
730 |
$42K |
| 71046 |
Radiologic examination, chest; 2 views |
5,518 |
5,211 |
$38K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
16,976 |
13,597 |
$35K |
| 80053 |
Comprehensive metabolic panel |
32,903 |
28,173 |
$27K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
2,353 |
2,172 |
$18K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
141 |
137 |
$16K |
| 80320 |
|
3,594 |
3,325 |
$14K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
1,084 |
1,015 |
$13K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
5,320 |
4,654 |
$13K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
19,028 |
16,836 |
$12K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
4,470 |
4,056 |
$11K |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
17 |
12 |
$9K |
| 74018 |
|
1,409 |
1,342 |
$8K |
| 73030 |
|
1,080 |
959 |
$7K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,786 |
1,532 |
$7K |
| 70498 |
|
193 |
184 |
$6K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
15,590 |
12,973 |
$6K |
| 73562 |
|
1,316 |
1,164 |
$6K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,100 |
774 |
$6K |
| 43235 |
|
12 |
12 |
$6K |
| 71045 |
Radiologic examination, chest; single view |
12,243 |
11,174 |
$6K |
| 73130 |
|
915 |
837 |
$6K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
5,085 |
4,890 |
$6K |
| 87631 |
|
1,762 |
1,717 |
$6K |
| 93976 |
|
2,052 |
1,900 |
$5K |
| 96376 |
|
5,068 |
3,620 |
$4K |
| 72100 |
|
393 |
369 |
$4K |
| 73630 |
|
998 |
939 |
$4K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
5,183 |
4,356 |
$3K |
| 73610 |
|
1,044 |
966 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,523 |
1,936 |
$3K |
| J3490 |
Unclassified drugs |
20,111 |
10,033 |
$3K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
35,485 |
30,319 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
5,991 |
5,059 |
$2K |
| 70486 |
|
28 |
27 |
$2K |
| 73110 |
|
379 |
343 |
$2K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
12,850 |
11,448 |
$2K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
7,427 |
6,872 |
$1K |
| 83690 |
|
13,017 |
11,652 |
$1K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
16 |
14 |
$973.46 |
| 81025 |
|
7,973 |
7,458 |
$965.86 |
| 87081 |
|
804 |
776 |
$909.49 |
| 84484 |
|
10,537 |
7,101 |
$898.90 |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
19 |
15 |
$853.43 |
| 81001 |
|
14,221 |
12,836 |
$758.22 |
| 82947 |
|
8,862 |
5,475 |
$731.08 |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
376 |
327 |
$730.06 |
| 83605 |
|
5,361 |
4,247 |
$615.97 |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,704 |
2,493 |
$576.19 |
| 87186 |
|
1,839 |
1,654 |
$533.61 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
3,200 |
2,742 |
$524.67 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,221 |
1,183 |
$485.77 |
| 84703 |
|
2,955 |
2,815 |
$484.96 |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
314 |
292 |
$462.71 |
| J2704 |
Injection, propofol, 10 mg |
4,139 |
3,769 |
$456.57 |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
16 |
15 |
$309.60 |
| 84702 |
|
2,989 |
2,733 |
$308.98 |
| 83880 |
|
1,550 |
1,401 |
$291.80 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
8,224 |
6,519 |
$291.48 |
| 73502 |
|
41 |
39 |
$291.22 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
8,324 |
7,750 |
$291.01 |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
18,908 |
9,747 |
$278.19 |
| 83735 |
|
5,549 |
4,681 |
$252.19 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
507 |
501 |
$245.34 |
| 85055 |
|
157 |
134 |
$244.15 |
| 87040 |
|
4,053 |
2,053 |
$238.44 |
| 87088 |
|
5,363 |
4,797 |
$229.76 |
| 87077 |
|
2,399 |
2,063 |
$227.78 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
8,273 |
7,095 |
$223.02 |
| 71101 |
|
16 |
13 |
$202.87 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,304 |
1,120 |
$189.86 |
| 85379 |
|
1,470 |
1,402 |
$188.91 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,593 |
1,528 |
$171.33 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
14,368 |
12,291 |
$152.79 |
| J8597 |
Antiemetic drug, oral, not otherwise specified |
3,350 |
3,029 |
$135.22 |
| 86769 |
|
276 |
272 |
$128.88 |
| 81003 |
|
7,601 |
7,055 |
$120.68 |
| 76801 |
|
779 |
688 |
$111.71 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
5,316 |
4,959 |
$105.78 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
3,585 |
3,177 |
$96.19 |
| 85610 |
|
4,651 |
4,000 |
$92.66 |
| 90715 |
|
246 |
237 |
$91.41 |
| 85027 |
|
2,877 |
2,335 |
$88.47 |
| 86850 |
|
1,671 |
1,518 |
$86.12 |
| 12011 |
|
25 |
25 |
$84.29 |
| 82550 |
|
1,102 |
976 |
$83.09 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
835 |
719 |
$74.20 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
305 |
292 |
$55.56 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
1,040 |
928 |
$52.52 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
150 |
142 |
$51.29 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
153 |
144 |
$51.29 |
| A9270 |
Non-covered item or service |
11,625 |
2,879 |
$51.03 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
373 |
196 |
$48.22 |
| 87807 |
|
404 |
388 |
$47.91 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
5,004 |
4,377 |
$46.97 |
| 86901 |
|
2,270 |
2,061 |
$46.03 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
3,467 |
2,895 |
$43.54 |
| 86900 |
|
1,823 |
1,668 |
$39.26 |
| 86140 |
|
1,659 |
1,473 |
$36.67 |
| 82803 |
|
158 |
132 |
$23.54 |
| 85730 |
|
1,445 |
1,303 |
$22.91 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
2,436 |
2,202 |
$21.32 |
| J1815 |
Injection, insulin, per 5 units |
585 |
336 |
$20.65 |
| J2060 |
Injection, lorazepam, 2 mg |
1,593 |
1,350 |
$18.53 |
| 96367 |
|
288 |
250 |
$13.97 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
310 |
289 |
$13.82 |
| 84100 |
|
469 |
371 |
$12.79 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
1,149 |
999 |
$12.23 |
| 12001 |
|
119 |
112 |
$12.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
2,322 |
1,866 |
$11.76 |
| J1790 |
Injection, droperidol, up to 5 mg |
498 |
451 |
$9.78 |
| 82010 |
|
40 |
37 |
$9.58 |
| 82565 |
|
172 |
151 |
$5.93 |
| J1630 |
Injection, haloperidol, up to 5 mg |
91 |
78 |
$5.62 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
3,378 |
3,125 |
$5.37 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
557 |
501 |
$4.09 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
550 |
524 |
$3.43 |
| J7999 |
Compounded drug, not otherwise classified |
749 |
704 |
$2.48 |
| J2175 |
Injection, meperidine hydrochloride, per 100 mg |
814 |
746 |
$0.24 |
| S0028 |
Injection, famotidine, 20 mg |
422 |
336 |
$0.00 |
| 84156 |
|
73 |
63 |
$0.00 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
36 |
28 |
$0.00 |
| 94664 |
|
46 |
43 |
$0.00 |
| C9113 |
Injection, pantoprazole sodium, per vial |
266 |
175 |
$0.00 |
| 84550 |
|
78 |
65 |
$0.00 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
30 |
26 |
$0.00 |
| 87210 |
|
322 |
301 |
$0.00 |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
118 |
102 |
$0.00 |
| 73590 |
|
15 |
14 |
$0.00 |
| 97161 |
|
42 |
37 |
$0.00 |
| 97116 |
|
19 |
12 |
$0.00 |
| 84460 |
|
44 |
40 |
$0.00 |
| Q0244 |
Injection, casirivimab and imdevimab, 1200 mg |
13 |
12 |
$0.00 |
| 84112 |
|
21 |
13 |
$0.00 |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
35 |
13 |
$0.00 |
| 84450 |
|
29 |
26 |
$0.00 |
| 84145 |
|
25 |
24 |
$0.00 |
| J1644 |
Injection, heparin sodium, per 1000 units |
17 |
12 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
64 |
54 |
$0.00 |
| J7510 |
Prednisolone oral, per 5 mg |
40 |
38 |
$0.00 |
| 82570 |
|
16 |
12 |
$0.00 |
| 10060 |
|
16 |
15 |
$0.00 |
| 84439 |
|
37 |
33 |
$0.00 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
13 |
12 |
$0.00 |
| 84520 |
|
39 |
36 |
$0.00 |
| 80329 |
|
660 |
556 |
$0.00 |
| C9399 |
Unclassified drugs or biologicals |
439 |
404 |
$0.00 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
728 |
525 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
2,194 |
1,902 |
$0.00 |
| 88304 |
|
203 |
183 |
$0.00 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
370 |
333 |
$0.00 |
| 94760 |
|
149 |
108 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
44 |
40 |
$0.00 |
| J3480 |
Injection, potassium chloride, per 2 meq |
71 |
52 |
$0.00 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
77 |
59 |
$0.00 |
| 76830 |
Ultrasound, transvaginal |
251 |
235 |
$0.00 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
14 |
13 |
$0.00 |
| 84132 |
|
41 |
36 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
138 |
131 |
$0.00 |
| 94644 |
|
69 |
68 |
$0.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
14 |
12 |
$0.00 |
| J0500 |
Injection, dicyclomine hcl, up to 20 mg |
32 |
30 |
$0.00 |
| 36410 |
|
14 |
13 |
$0.00 |
| 87070 |
|
32 |
13 |
$0.00 |
| 87205 |
|
33 |
14 |
$0.00 |
| 85652 |
|
59 |
52 |
$0.00 |
| 85018 |
|
35 |
25 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
101 |
95 |
$0.00 |
| 76819 |
Fetal biophysical profile; without non-stress testing |
18 |
13 |
$0.00 |
| A9585 |
Injection, gadobutrol, 0.1 ml |
29 |
26 |
$0.00 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
14 |
14 |
$0.00 |